Cellestis | GenomeWeb

Cellestis

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Qiagen today said that it has completed the acquisition of all of the ordinary shares of Melbourne, Australia-based Cellestis for A$3.80 (US$4.04) per share.

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Cellestis announced on Tuesday that the Supreme Court of Victoria in Australia has approved Qiagen's acquisition of its ordinary shares by way of a Scheme of Arrangement.

Shareholders overwhelmingly approved an amended proposal that will result in Qiagen paying around $374 million to acquire the Australian firm.

Qiagen's offer represents a premium of roughly 41 percent premium to the three-month volume-weighted average price of Cellestis' shares ending on April 1.

With the help of QuantiFeron tests in the first-line setting, Qiagen is hoping to improve the capabilities of its DNA and RNA diagnostics in preventing and profiling disease and delivering personalized care.

The deal provides Qiagen with access to Cellestis' QuantiFeron "pre-molecular" testing technology for detecting and monitoring disease.

Sequencing of a 10,000-year-old mummy leads to its repatriation to the Fallon Paiute-Shoshone Tribe, Nature News reports.

The final text of the bill to reauthorize the America COMPETES Act might smooth over the differences between NSF and the House science committee, ScienceInsider says.

Four Republican lawmakers urge President-elect Donald Trump to keep Francis Collins as NIH director, Stat News reports.

In Genome Research this week: Platinum variant catalog, algorithmic strategy for upgrading fragmented assemblies, and more.